Eckert & Ziegler BEBIG, Mick Radio-Nuclear Instruments, WOLF-Medizintechnik (WOmed)


Wir halten Sie auf dem Laufenden! Wenn Sie Fragen zu unseren Pressemitteilungen haben, können Sie uns gerne über das Kontaktformular der Website kontaktieren. Bleiben Sie über die neuesten Nachrichten unseres Unternehmens auf dem Laufenden:

Eckert & Ziegler BEBIG announces launch of I-125 IsoSeed® S17plus for LDR prostate brachytherapy

Seneffe, Belgium, December 10, 2015, Eckert & Ziegler BEBIG has launched its latest sealed source model I-125 IsoSeed® S17plus which received the CE mark on December 4, 2015.

I-125 IsoSeed®

The new seed combines the fundamental roots of LDR prostate brachytherapy by using a full-length silver marker in accordance with the most recent manufacturing standards. "With IsoSeed® S17plus, we offer a seed that fulfils the latest customer requests and strengthens our position as a leading seed manufacturer and complete brachytherapy provider. The new seed is available in a wider range of activities with an apparent activity of between 0.197 and 0.926 mCi and it continues to provide a high degree of visibility under X-ray, fluoroscopy, CT-scan, MRI and ultrasound." explains Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG.

IsoSeed® I-125 S17plus will replace the IsoSeed® I-125 S17, which has been sold since 2005 in more than 15 countries, and this new version is now available. Dr. Hasselmann adds: "We are confident that we will be able to market IsoSeed® I-125 S17plus in even more countries than the previous version, the IsoSeed® I-125 S17, thereby increasing our total sales once more."

Like the S17, the S17plus is sold as loose seeds intended for use with the MickTM Applicator and as strands in the form of the IsoCord® and IsoStrand®.

About LDR brachytherapy

In this form of treatment, small radioactive iodine-125 sources, so called seeds, are placed inside the prostate. By placing the seeds evenly throughout the organ, the prostate is covered with the designated dose required to destroy the cancerous cells. Since irradiation is mainly localized around the radioactive source, neighboring tissues are spared unnecessary damage.

LDR or permanent brachytherapy is the most conservative treatment method for early-stage prostate cancer. Its international popularity has increased continuously since the early 1990s and it is now generally accepted as a state-of-the art therapy. Prostate seed implantation is an effective and well-tolerated method for curing prostate cancer. The cure rates are comparable to the ones of external beam radiation therapy and prostatectomy for early-stage prostate cancer.

About Eckert & Ziegler BEBIG

Contributing to saving lives!

Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treat­ment of cancer using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and in the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Eckert & Ziegler BEBIG employs approximately 150 people. The company has been listed on the Euronext stock exchange since April 1997.

Annica Witt
Marketing Communication Manager